• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多肝病灶患者肝细胞癌治疗方式的选择

Selection of therapeutic modalities for hepatocellular carcinoma in patients with multiple hepatic lesions.

作者信息

Monden M, Sakon M, Gotoh M, Kanai T, Umeshita K, Wang K S, Sakurai M, Kuroda C, Okamura J, Mori T

机构信息

Department of Surgery II, Osaka University Medical School, Japan.

出版信息

Cancer Chemother Pharmacol. 1992;31 Suppl:S38-44. doi: 10.1007/BF00687103.

DOI:10.1007/BF00687103
PMID:1333907
Abstract

In the present study, we compared the survival of patients with multi tumor hepatocellular carcinoma (HCC) following their treatment with liver resection versus TAE. A total of 336 HCC patients were treated at Osaka University Hospital between 1980 and 1989. Of these, 140 patients underwent liver resection in the presence or absence of TAE and 173 subjects were treated with TAE alone. Our TAE protocol consisted of 50 mg Adriamycin, 3-5 ml lipiodol, and Gelfoam. The 1-, 3-, and 5-year survival values found for the liver resection group were 87.4%, 66.0%, and 47.4%, respectively, whereas the values calculated for the TAE group were 64.6%, 29.9%, and 15.8%, respectively. The survival of patients in the resection group was clearly better than that of subjects in the TAE group. Of the 140 patients who underwent resection, 36 cases were proven to have multiple lesions by histopathological examination. The 1- and 3-year survival values determined for this special group were 67.9% and 33.3%, respectively. Of the TAE cases, 113 were diagnosed as having multiple lesions by imaging examination, and their 1- and 3-year survival values were 59.7% and 24.9%, respectively. No significant differences in survival was found between these two different treatment modalities for these multiple-lesion cases. The results of this study indicate that it is unlikely that surgical resection is superior to TAE alone for the treatment of HCC patients with multiple lesions.

摘要

在本研究中,我们比较了多肿瘤肝细胞癌(HCC)患者接受肝切除与经动脉栓塞化疗(TAE)治疗后的生存率。1980年至1989年期间,大阪大学医院共治疗了336例HCC患者。其中,140例患者在有或无TAE的情况下接受了肝切除,173例患者仅接受了TAE治疗。我们的TAE方案包括50毫克阿霉素、3 - 5毫升碘油和明胶海绵。肝切除组的1年、3年和5年生存率分别为87.4%、66.0%和47.4%,而TAE组计算得出的生存率分别为64.6%、29.9%和15.8%。切除组患者的生存率明显高于TAE组。在接受切除的140例患者中,经组织病理学检查证实有36例存在多个病灶。该特殊组确定的1年和3年生存率分别为67.9%和33.3%。在TAE病例中,113例经影像学检查诊断为有多个病灶,其1年和3年生存率分别为59.7%和24.9%。对于这些多病灶病例,这两种不同治疗方式的生存率没有发现显著差异。本研究结果表明,对于治疗有多个病灶的HCC患者,手术切除不太可能优于单纯TAE。

相似文献

1
Selection of therapeutic modalities for hepatocellular carcinoma in patients with multiple hepatic lesions.多肝病灶患者肝细胞癌治疗方式的选择
Cancer Chemother Pharmacol. 1992;31 Suppl:S38-44. doi: 10.1007/BF00687103.
2
Assessment of chemoembolization therapy for primary liver cancer using a stabilized adriamycin-lipiodol suspension.使用稳定的阿霉素-碘油混悬液评估原发性肝癌的化疗栓塞治疗。
Cancer Chemother Pharmacol. 1992;31 Suppl:S60-4. doi: 10.1007/BF00687107.
3
Short article: Management of ruptured hepatocellular carcinoma in a European tertiary care center.短文:欧洲一家三级医疗中心肝细胞癌破裂的管理
Eur J Gastroenterol Hepatol. 2016 Aug;28(8):963-6. doi: 10.1097/MEG.0000000000000652.
4
Significance of multidisciplinary therapy for hepatocellular carcinoma.多学科治疗对肝细胞癌的意义。
Cancer Chemother Pharmacol. 1992;31 Suppl:S13-9. doi: 10.1007/BF00687098.
5
Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer.与化疗栓塞相比,经动脉注射(131)I-碘油治疗不可切除肝细胞癌。
J Nucl Med. 2009 Jun;50(6):871-7. doi: 10.2967/jnumed.108.060558. Epub 2009 May 14.
6
Effectiveness of Lipiodol in transcatheter arterial embolization of hepatocellular carcinoma.碘油在肝细胞癌经导管动脉栓塞中的有效性。
Cancer Chemother Pharmacol. 1992;31 Suppl:S72-6. doi: 10.1007/BF00687110.
7
Efficacy of transcatheter embolization/chemoembolization (TAE/TACE) for the treatment of single hepatocellular carcinoma.经导管栓塞术/化疗栓塞术(TAE/TACE)治疗单发性肝细胞癌的疗效
World J Gastroenterol. 2007 Jun 7;13(21):2952-5. doi: 10.3748/wjg.v13.i21.2952.
8
Survival Outcome Between Hepatic Resection and Transarterial Embolization for Hepatocellular Carcinoma More Than 10 cm: A Propensity Score Model.10厘米以上肝细胞癌肝切除与经动脉栓塞的生存结果:倾向评分模型
World J Surg. 2015 Jun;39(6):1510-8. doi: 10.1007/s00268-015-2975-y.
9
Indication of chemoembolization therapy without gelatin sponge for hepatocellular carcinoma.无明胶海绵的化疗栓塞疗法用于肝细胞癌的指征
Semin Oncol. 1997 Apr;24(2 Suppl 6):S6-110-S6-115.
10
[Analysis of survival in 240 patients with unresectable primary hepatocellular carcinoma treated with hepatic artery chemo-embolization].
Zhonghua Zhong Liu Za Zhi. 1996 Sep;18(5):362-4.

引用本文的文献

1
CT volume measurement for prognostic evaluation of unresectable hepatocellular carcinoma after TACE.CT 容积测量在 TACE 后不可切除肝癌预后评估中的应用。
World J Gastroenterol. 2010 Apr 28;16(16):2038-45. doi: 10.3748/wjg.v16.i16.2038.
2
Combined hepatocholangiocarcinoma: case-series and review of literature.肝内胆管癌合并症:病例系列及文献综述
Int J Gastrointest Cancer. 2006;37(1):27-34. doi: 10.1385/IJGC:37:1:27.
3
Sequential transarterial chemoembolization for unresectable advanced hepatocellular carcinoma.不可切除的晚期肝细胞癌的序贯经动脉化疗栓塞术

本文引用的文献

1
An appraisal of transcatheter arterial embolization combined with transcatheter arterial infusion of chemotherapeutic agent for hepatic malignancies.经导管动脉栓塞联合经导管动脉灌注化疗药物治疗肝恶性肿瘤的评估
World J Surg. 1982 May;6(3):352-7. doi: 10.1007/BF01653556.
2
Surgical anatomy and anatomical surgery of the liver.肝脏的外科解剖学与解剖学手术
World J Surg. 1982 Jan;6(1):3-9. doi: 10.1007/BF01656368.
3
A multiple regression equation for prediction of posthepatectomy liver failure.一个用于预测肝切除术后肝衰竭的多元回归方程。
Cardiovasc Intervent Radiol. 1996 Nov-Dec;19(6):388-96. doi: 10.1007/BF02577625.
4
Current treatment modalities for hepatocellular carcinoma.肝细胞癌的当前治疗方式。
Ann Surg. 1994 Mar;219(3):236-47. doi: 10.1097/00000658-199403000-00003.
5
New development of transarterial immunoembolization (TIE) for therapy of hepatocellular carcinoma with intrahepatic metastases.经动脉免疫栓塞术(TIE)治疗肝细胞癌肝内转移的新进展。
Cancer Chemother Pharmacol. 1994;33 Suppl:S48-54. doi: 10.1007/BF00686668.
6
Evaluation of the therapeutic effect of TAE on primary liver cancer.
Cancer Chemother Pharmacol. 1994;33 Suppl:S55-9. doi: 10.1007/BF00686669.
Ann Surg. 1984 Nov;200(5):658-63. doi: 10.1097/00000658-198411000-00018.
4
Transcatheter chemo-embolization effective for treating hepatocellular carcinoma. A histopathologic study.
Cancer. 1984 Aug 1;54(3):387-92. doi: 10.1002/1097-0142(19840801)54:3<387::aid-cncr2820540303>3.0.co;2-w.
5
Prognosis of primary hepatocellular carcinoma.
Hepatology. 1984 Jan-Feb;4(1 Suppl):3S-6S. doi: 10.1002/hep.1840040703.
6
Limited hepatic resection effective for selected cirrhotic patients with primary liver cancer.有限肝切除术对特定的原发性肝癌肝硬化患者有效。
Ann Surg. 1984 Jan;199(1):51-6. doi: 10.1097/00000658-198401000-00009.
7
Postoperative prognosis as related to blood ketone body ratios in hepatectomized patients.
Eur Surg Res. 1983;15(6):302-11. doi: 10.1159/000128373.
8
Hepatic artery embolization in 120 patients with unresectable hepatoma.120例不可切除肝癌患者的肝动脉栓塞术
Radiology. 1983 Aug;148(2):397-401. doi: 10.1148/radiology.148.2.6306721.
9
Hepatic resection in 125 patients.125例患者接受肝切除术。
Arch Surg. 1984 Sep;119(9):1025-32. doi: 10.1001/archsurg.1984.01390210029008.
10
Transection of the oesophagus for bleeding oesophageal varices.为治疗食管静脉曲张出血而行食管横断术。
Br J Surg. 1973 Aug;60(8):646-9. doi: 10.1002/bjs.1800600817.